FY2028 EPS Estimates for HealthEquity Cut by Zacks Research

HealthEquity, Inc. (NASDAQ:HQY) – Zacks Research decreased their FY2028 earnings per share (EPS) estimates for shares of HealthEquity in a research note issued to investors on Tuesday, April 15th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.62 for the year, down from their previous forecast of $4.65. The consensus estimate for HealthEquity’s current full-year earnings is $2.32 per share.

HQY has been the topic of several other reports. Barrington Research reissued an “outperform” rating and issued a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. The Goldman Sachs Group reduced their target price on HealthEquity from $107.00 to $94.00 and set a “neutral” rating for the company in a report on Thursday, March 27th. KeyCorp dropped their price target on HealthEquity from $110.00 to $100.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wells Fargo & Company lifted their target price on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Raymond James raised shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and lowered their price objective for the company from $120.00 to $115.00 in a research report on Tuesday, March 25th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $111.75.

HealthEquity Trading Down 0.4 %

NASDAQ:HQY opened at $83.03 on Wednesday. The stock has a fifty day simple moving average of $96.47 and a 200 day simple moving average of $96.35. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $7.18 billion, a price-to-earnings ratio of 76.17, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49. HealthEquity has a 1-year low of $65.01 and a 1-year high of $115.59.

Institutional Investors Weigh In On HealthEquity

Institutional investors have recently added to or reduced their stakes in the company. Fifth Third Bancorp grew its holdings in shares of HealthEquity by 17.5% during the 1st quarter. Fifth Third Bancorp now owns 955 shares of the company’s stock worth $84,000 after purchasing an additional 142 shares in the last quarter. Integrated Advisors Network LLC acquired a new position in shares of HealthEquity in the 1st quarter valued at $259,000. SG Americas Securities LLC lifted its holdings in shares of HealthEquity by 7.1% during the 1st quarter. SG Americas Securities LLC now owns 5,843 shares of the company’s stock worth $516,000 after acquiring an additional 388 shares during the period. Curated Wealth Partners LLC boosted its position in shares of HealthEquity by 16.9% during the 1st quarter. Curated Wealth Partners LLC now owns 2,946 shares of the company’s stock valued at $260,000 after acquiring an additional 425 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in HealthEquity by 25.9% in the first quarter. GAMMA Investing LLC now owns 1,571 shares of the company’s stock worth $139,000 after purchasing an additional 323 shares in the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the sale, the director now owns 78,219 shares of the company’s stock, valued at $8,704,992.51. This trade represents a 6.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the company’s stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $78.26, for a total value of $695,027.06. Following the transaction, the executive vice president now owns 56,655 shares of the company’s stock, valued at approximately $4,433,820.30. This trade represents a 13.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,381 shares of company stock worth $1,781,432. 2.20% of the stock is owned by insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.